Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q2 2026 · 10-Q
Revenue$0.00$0.00— vs Q2 2025 Net Income-$110.85K-$110.85KN/M vs Q2 2025 EPS Diluted$0.00$0.00— vs Q2 2025 Operating Income-$99,067N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
derived
ended Jul 31, 2025 · filed Jun 17, 2026 · 321 d after period end